MedTrace Logo

The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT

NCT03902041 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2019-04-03

No results posted yet for this study

Summary

This study evaluates the addition of Eltrombopag after Hematopoietic stem cell transplantation (HSCT) to improve the engraftment of hematopoietic stem cell. Half of the participants will receive Eltrombopag,while the other will not receive the Eltrombopag.

Conditions

  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Eltrombopag

Interventions

DRUG

Eltrombopag

The patients will receive Eltrombopag treatment after transplantation

Sponsors & Collaborators

  • Shandong Provincial Hospital

    lead OTHER_GOV

Principal Investigators

  • Xin Wang · Shandong Provincial Hospital

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2022-04-30
Completion
2022-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03902041 on ClinicalTrials.gov